Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 3, 2014, Pages 446-451

  Ebina, Yasuhiko ^a   Watari, Hidemichi ^b   Kaneuchi, Masanori ^b   Takeda, Mahito ^b   Hosaka, Masayoshi ^b   Kudo, Masataka ^b   Yamada, Hideto ^a   Sakuragi, Noriaki ^b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytoreduction; FDG PET; Ovarian cancer; Recurrence

Indexed keywords

ADULT; AGED; DISSECTION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84894259093     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2610-9     Document Type: Article

References (19)

1. Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933-9. (Pubitemid 43673208)
2. Salani R, Santillan A, Zahurak ML, Giuntoli 2nd RL, Gardner GJ, Armstrong DK, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109:685-91. (Pubitemid 46233229)
3. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265-74.
4. Hising C, Anjegard IM, Einhorn N. Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients. Am J Clin Oncol. 1991;14:111-4.
5. Zanaboni F, Presti M, Scarfone G, Bolis G. CA 125 reliability in predicting ovarian cancer recurrence. Tumori. 1989;75:69-71. (Pubitemid 19119895)
6. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155-63.
7. Tanner EJ, Chi DS, Eisenhauer EL, Diaz-Montes TP, Santillan A, Bristow RE. Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol. 2010;117:336-40.
8. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996;7:361-4. (Pubitemid 26246787)
9. Ferrozzi F, Bova D, De Chiara F, Garlaschi G, Draghi F, Cocconi G, et al. Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical history. Clin Imaging. 1998;22:364-70. (Pubitemid 28445815)
10. Garcia-Velloso MJ, Jurado M, Ceamanos C, Aramendia JM, Garrastachu MP, Lopez-Garcia G, et al. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:1396-405. (Pubitemid 47312579)
11. Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol. 2006;103:271-6. (Pubitemid 44374699)
12. Sebastian S, Lee SI, Horowitz NS, Scott JA, Fischman AJ, Simeone JF, et al. PET-CT vs CT alone in ovarian cancer recurrence. Abdom Imaging. 2008;33:112-8.
13. Limei Z, Yong C, Yan X, Shuai T, Jiangyan X, Zhiqing L. Accuracy of positron emission tomography/computed tomography in the diagnosis and restaging for recurrent ovarian cancer: a meta-analysis. Int J Gynecol Cancer. 2013;23:598-607.
14. Soussan M, Wartski M, Cherel P, Fourme E, Goupil A, Le Stanc E, et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol Oncol. 2008;108:160-5. (Pubitemid 350299439)
15. Mangili G, Picchio M, Sironi S, Vigano R, Rabaiotti E, Bornaghi D, et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur J Nucl Med Mol Imaging. 2007;34:658-66. (Pubitemid 46669366)
16. Fulham MJ, Carter J, Baldey A, Hicks RJ, Ramshaw JE, Gibson M. The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol. 2009;112:462-8.
17. Shih KK, Chi DS, Barakat RR, Leitao Jr MM. Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series. Gynecol Oncol. 2010;117:330-5.
18. Palomar A, Nanni C, Castellucci P, Ambrosini V, Montini GC, Allegri V, et al. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. Mol Imaging Biol. 2012;14:123-9.
19. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol. 2001;82:17-21. (Pubitemid 32634948)